Moomoo AI 已提取核心信息
EyePoint Pharmaceuticals Inc officer Dario A Paggiarino is set to sell 66,311 shares of common stock on January 23, 2024. The shares to be sold were acquired on the same date through the exercise of stock options, with the securities obtained directly from the issuer. The transaction is a cash exercise, and the aggregate market value of the shares to be sold is approximately $1,590,137.78. This planned sale follows a three-month period where Paggiarino sold a total of 54,996 shares, grossing $1,187,034.19.
EyePoint Pharmaceuticals Inc officer Dario A Paggiarino is set to sell 66,311 shares of common stock on January 23, 2024. The shares to be sold were acquired on the same date through the exercise of stock options, with the securities obtained directly from the issuer. The transaction is a cash exercise, and the aggregate market value of the shares to be sold is approximately $1,590,137.78. This planned sale follows a three-month period where Paggiarino sold a total of 54,996 shares, grossing $1,187,034.19.
EyePoint Pharmicals Inc高管达里奥·帕贾里诺定于2024年1月23日出售66,311股普通股。待售股票于同日通过行使股票期权收购，证券直接从发行人处获得。该交易是现金交易，待售股票的总市值约为1,590,137.78美元。此次计划出售是在三个月之后进行的，帕贾里诺共出售了54,996股股票，总收入为1,187,034.19美元。
EyePoint Pharmicals Inc高管达里奥·帕贾里诺定于2024年1月23日出售66,311股普通股。待售股票于同日通过行使股票期权收购，证券直接从发行人处获得。该交易是现金交易，待售股票的总市值约为1,590,137.78美元。此次计划出售是在三个月之后进行的，帕贾里诺共出售了54,996股股票，总收入为1,187,034.19美元。
有用
没用
